J.&J.’s vaccine should carry warning of potential risk for rare blood clots, the E.U.’s regulator says, but believes benefits outweigh risks.

The European Medicines Agency did not recommend stopping use of the vaccine, leaving the decision on whether and how to limit it up to individual E.U. countries.